| Literature DB >> 32274117 |
Chengyao Guo1, Guiling Xiang2, Liang Xie2, Zilong Liu2, Xiaomin Zhang1, Qinhan Wu2, Shanqun Li2, Yan Wu1.
Abstract
BACKGROUND: Tai Chi is a systematic whole body movement developed in ancient China. It plays an increasingly important role in the field of pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD). Our review aimed to explore the impact of Tai Chi on the physical and mental health of patients with COPD.Entities:
Keywords: Tai Chi; chronic obstructive pulmonary disease (COPD); meta-analysis; traditional Chinese exercise
Year: 2020 PMID: 32274117 PMCID: PMC7139037 DOI: 10.21037/jtd.2020.01.03
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 3.005
PRISMA 2009 checklist word
| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| Title | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| Abstract | |||
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2-3 |
| Introduction | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3-5 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 5 |
| Methods | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 5-6 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 5-6 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 5-6 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 6 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 6-7 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 6 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 7 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 7 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | 7 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 7 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 7 |
| Results | |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 8-9 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 9-11 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 11-13 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 10-23 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 10-23 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 11-13 |
| Additional analysis | 23 | Give results of additional analyses, if done [e.g., sensitivity or subgroup analyses, meta-regression (see Item 16)]. | |
| Discussion | |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 24-28 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 28-29 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 29 |
| Funding | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 30 |
From: Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
Figure 1Flowchart of study selection.
Characteristics of included studies
| Article, year | Country of performed | Language of publication | Sample | dropout in each group with | Age, y, mean | Duration of COPD, y | Disease severity | Comparison arms | Treatment dosage | Exercise contents | Outcomes | Time point |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhu | China | English | G1: 30; | G1: had no interest [3]; | G1: 67.87 [5.22]. G2: 68.10 [6.57] | G1: 7.3 [4.8]. | G2: 22%; G3: 42%; G4: 36%. Total mean FEV1% 37.94 [14.85] | G1: TC (simplified | 40–50 min/session; 3 sessions/week; 3 months | NA | (I) Lung function (FEV1%); | 3 months; |
| Pan | China | Chinese | G1: 23; | G1: other disease [1]; | NA | NA | G1: FEV1% 52.80 [3.12]; G2: FEV1% 52.05 [3.27] | G1: TC (simplified and modified 24-form | 30 min/session; 3 sessions/week; 2 months | NA | (I) HRQoL (SGRQ); (II) Exercise capacity (6MWD); (III) Lung function (FVC, FEV1, FVC%, FEV1%); (IV) Anxiety and depression (HAD); (V) Health status (CAT) | 2 months |
| Polkey 2018 ( | China | English | G1: 60 | G1: adverse event [2]; | NA | NA | Total mean FEV1% predicted:43.6 | G1: TC (24 form Yang style); G2: exercise | G1: 1 h/session; 5 sessions/week; 3 months. G2: 1 h/session; 3 sessions/week; 3 months | 50% resistance exercises (arm and leg weights aiming for a target 70–80% of their one-repetition maximum), hybrid (rowing machine), and 50% progressive aerobic whole body exercise (e.g., cycle or treadmill) | (I) Exercise capacity (6MWT); (II) Lung function (FEV1,FVC); (III) HRQoL (SGRQ) | 3 months; |
| Ni 2017 ( | China | Chinese | G1: 30; | NA | G1: 65.3 [2.1]; | G1: 10.9 [2.2]; G2: 11.6 [2.5]; G3: 9.6 [3.5] | NA | G1: TC; G2: Yoga; | G1: 30 min/day; 6 months. | NA | Lung function (FVC, FEV1, FEV1%) | 6 months |
| Ren | China | Chinese | G1: 30; | NA | G1: 59.2 [4.5]; | G1: 2.4 [1.9]; | Total: G2: 30; | G1: TC; | 1 h/session; 2 sessions/week; 3 months | Reducing lip breathing, abdominal breathing exercise, breathing muscle strength exercise, power car exercise, plate exercise | (I) Exercise capacity (6MWT); | 3 months |
| Ng | Hong Kong, China | English | G1: 94; | G1, G2: health problem; | G1: 74.16 [6.46]; G2: 74.13 [6.81] | G1: 7.11 [10.33]; G2: 8.68 [10.99] | Total: G1 [%]: 39 [20.3]; G2 [%]: 78 [40.6]; G3 [%]: 58 [30.2]; G4 [%]: 17 [8.9] | G1: TC (Sun-style TC); G2: exercise | 80 min/session; | 5 min warm-up exercises, two aerobic activities including treadmill exercise and lower limb ergometry exercise lasting for 20 min | (I) HRQoL (SGRQ-HKC); | 2 months; |
| Zhang | China | Chinese | G1: 18; | NA | G1: 68.02 [6.91]; G2: 67.21 [5.96]; G3: 66.82 [6.33]; G4: 66.71 [5.84] | G1: 33.41 [2.45]; G2: 32.92 [2.15]; G3: 35.32 [2.35]; G4: 32.84 [1.98] | G1: 11; G2: 54; | G1: TC (simplified and modified 24-form Tai Chi); G2: Exercise (BE); G3: TC + exercise; G4: control | G1: 1 h/day; | Combined constricted abdominal breathing | (I) Lung function (FEV1,FEV1/FVC, FEV1%); (II) Exercise capacity (6MWT); | 12 months |
| Niu | China | English | G1: 20; | G2: Died [1] | G1: 59.7 [2.76]; | NA | G1: FEV1 [%]; predicted 41.9 [5.50]. | G1: TC; G2: control | 1 session/day; 4 sessions of supervised TC and 3 sessions of home-based TC/week; 6 months | NA | (I) Lung function (FEV1, FEV1% predicted); | 6 months |
| Chan 2013 ( | Hong Kong, China | English | G1: 70; | G1: joint pain [3]; hospital admission [4]; | G1: 71.7 [8.2]; | G1: 10.3 [9.3]; G2: 10.6 [8.8]; G3: 12.4 [10.6] | G1 [%]: 32 [15.5]; G2 [%]: 86 [41.7]; G3 [%]: 88 [42.8] | G1: TCQ; G2: exercise (BE + PE); G3: control | G1: two 60-minute sessions/week; 3 months. G2: NA | breathing exercise combined with walking as an exercise | HRQoL (SGRQ) | 6 weeks; |
| Leung 2013 ( | Australia | English | G1: 22; G2: 20 | G1: exacerbation [2]; | Total: 73 [8] | NA | Total mean FEV1% predicted 59 [16] | G1: TC (Short-form Sun-style tai chi). G2: control | 1 h/session; 2 supervised training sessions /week; and 30 min/session; 5 sessions/week; 3 months | NA | (I) HRQoL (CRQ); | 3 months |
| Chan 2013 ( | Hong Kong, China | English | G1: 70 | G1: Not in Hong Kong [5]; hospital admission [1]; no interest [1]; increased SOB [1]; no time [1]; died [1]. G2: refused [2]; default [2]. G3: no interest [16] | G1: 71.7 [8.2]; | G1: 10.3 [9.3]; G2: 10.6 [8.8]; G3: 12.4 [10.6] | G1: FEV1 [%]; Predicted 50.1 [21.8]. G2: FEV1 [%]; Predicted 56.4 [25.6]. G3: FEV1 [%]; Predicted 55.1 [23.3] | G1: TCQ (13-form TCQ); G2: exercise (BE + PE); G3: control | G1: 1 h/session; 2 sessions/ week; 3 months. G2: NA. | use pursed-lip breathing (PLB) and diaphragmatic | (I) Lung function (FVC, FEV1); | 3 months; |
| Du | China | Chinese | G1: 36; | NA | G1: 65.24 [8.37]; G2: 62.38 [6.24]; G3: 64.48 [6.54] | G1: 7.18 [2.72]; G2: 7.82 [3.09]; G3: 7.50 [2.85] | G1: 33 | G1: TC (24-form Yang-form Tai Jiquan); G2: exercise (BE + PE); G3: control | G1: 1 h/day; and 1 h/session; 2 sessions/week; 3 months. G2: 1.5 h/day; 3 months | Narrow lip abdominal | (I) HRQoL (SGRQ); | 6 weeks; |
| Du | China | Chinese | G1: 36; | NA | G1: 65.24 [8.37]; G2: 62.38 [6.24]; G3: 64.48 [6.54] | G1: 7.18 [2.72]; G2: 7.82 [3.09]; G3: 7.50 [2.85] | G1: 33; G2: 79 | G1: TC (24-form Yang-form Tai Jiquan); G2: exercise (BE + PE); G3: control | G1: 1 h/day; and 1 h/session; 2 sessions/week; 3 months. G2: 1.5 h/day; 3 months | Narrow lip abdominal | (I) Lung function (FEV1%, FEV1/FVC); | 6 weeks; |
| Chan 2011 ( | Hong Kong, China | English | G1: 70; | G1: hospital admission [4]; no interest [2]; increased SOB [2]; joint pain [3]; died [1]. G2: hospital admission [3]; no interest [10]; increased SOB [2]; joint pain [2]; Died [1]; Venue too far from home [1]. G3: no interest [11]; Increased SOB [2]; hospital admission [3]; default [3] | G1: 71.7 [8.2]; G2: 73.6 [7.5]; G3: 73.6 [7.4] | G1: 10.3 [9.3]; G2: 10.6 [8.8]; G3: 12.4 [10.6] | Total: G1 [%]: 32 [15.5]; G2 [%]: 86 [41.7]; G3 [%]: 88 [42.8] | G1: TCQ (13-form TCQ) G2: exercise (BE + PE); G1: control | G1: 1 hour/session; 2 sessions/week; 3 months. | pursed-lip breathing (PLB) and diaphragmatic breathing (DB) coordinated with self-paced walking | (I) Exercise capacity (6MWD); | 6 weeks; |
| Yeh | America | English | G1: 5; | G1: discontinued intervention [1] | G1: 65 [6]; G2: 66 [6] | NA | Total mean FEV1% predicted 50 [7] | G1: TC (Yang-style short form); G2: control | 1 hour/session; 2 sessions/week; 3 months | NA | (I) HRQoL (CRQ); (II) Exercise capacity (6MWT); (III) Lung function (FEV1/FVC) | 3 months |
| Zhou | China | Chinese | G1: 23; | NA | NA | NA | NA | G1: TC (simplified and modified 24-form Tai Chi); G2: control | 40 min/day; 4 months | NA | Lung function (FEV1, FVC, FEV1%) | 4 months |
N, number; SD, standard deviation; Y, year; COPD, chronic obstructive pulmonary disease; G1, group 1; G2, group 2; TC, Tai Chi; TCQ, Tai Chi Qigong; NA, not available; BE, breathing exercise; PE, physical exercise; CAT, COPD Assessment Test; FVC, forced volume capacity; FEV1% Pred, FEV1 percent predicted normal values; FEV1, forced expiratory volume in 1 s; FEV1/FVC, the ratio of FEV1 to FVC; HRQoL, health-related quality of life; CRQ, Chronic Respiratory Disease Questionnaire; 6MWD, six-minute walking distance; SGRQ-HKC, St. George’s Respiratory Questionnaire-Hong Kong Chinese version; SAS, Self-rating Anxiety Scale; SDS, Self-rating Depression Scale; SGRQ, St. George’s Respiratory Questionnaire; HAD, Hospital Anxiety and Depression Scale.
Risk of bias for included studies
| Study | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome assessment | Selective reporting | Other bias |
|---|---|---|---|---|---|---|---|
| Zhu 2018 ( | Low | Low | Low | Unclear | Low | Low | High |
| Pan 2018 ( | Low | Unclear | Unclear | Unclear | Low | Low | Low |
| Polkey 2018 ( | Unclear | Unclear | Unclear | Unclear | Low | Low | Low |
| Ni 2017 ( | Low | Unclear | Unclear | Unclear | Low | Low | Low |
| Ren 2017 ( | High | High | Unclear | Unclear | Low | Low | Low |
| Ng 2014 ( | Low | Low | Unclear | Low | Low | Low | Low |
| Zhang 2014 ( | Low | Unclear | Unclear | Unclear | Low | Low | Low |
| Niu 2014 ( | Low | Low | Low | Low | Low | Low | Low |
| Chan 2013 ( | Low | Low | Low | Low | High | Low | Low |
| Leung 2013 ( | Low | Low | Low | Low | Low | Low | Low |
| Chan 2013 ( | Low | Low | Unclear | Unclear | High | Low | Low |
| Du 2013 ( | Low | Unclear | Unclear | Unclear | Low | Low | Low |
| Du 2013 ( | Unclear | Unclear | Unclear | Unclear | Low | Low | Low |
| Chan 2011 ( | Low | Low | Unclear | Low | Low | Low | Low |
| Yeh 2010 ( | Low | Unclear | Unclear | Low | Low | Low | Low |
| Zhou 2009 ( | Unclear | Unclear | Low | Low | Low | Low | Low |
Figure 2Methodological quality graph.
Figure 3Methodological quality summary graph.
Figure 4Meta-analysis of Tai on FVC in short time intervention period. (A) Tai Chi group versus control group; (B) Tai Chi group versus exercise group. Short time intervention period: ≤3 months; medium time intervention period: 4–6 months; long time intervention period: >6 months. FVC, forced volume capacity.
Figure 5Meta-analysis of Tai on FEV1. (A) Tai Chi group versus control group; (B) Tai Chi group versus exercise group. Short time intervention period: ≤3 months; medium time intervention period: 4–6 month; long time intervention period: >6 months. FEV1, forced expiratory volume in 1 s.
Figure 6Meta-analysis of Tai on FEV1%. Tai Chi group versus control group. Short time intervention period: ≤3 months; medium time intervention period: 4–6 months; long time intervention period: >6 months. FEV1%, FEV1 percent predicted normal values.
Figure 7Meta-analysis of Tai on FEV1/FVC in short time intervention period. (A) Tai Chi group versus control group; (B) Tai Chi group versus exercise group. Short time intervention period: ≤3 months; medium time intervention period: 4–6 months; long time intervention period: >6 months. FEV1/FVC, the ratio of FEV1 to FVC.
Figure 8Meta-analysis of Tai on 6MWD. (A) Tai Chi group versus control group; (B) Tai Chi group versus exercise group. Short time intervention period: ≤3 months; medium time intervention period: 4–6 months; long time intervention period: >6 months. 6MWD, 6-minute walking distance.
Figure 9Meta-analysis of Tai on CAT. (A) Tai Chi group versus control group; (B) Tai Chi group versus exercise group in short time intervention period. Short time intervention period: ≤3 months; medium time intervention period: 4–6 months; long time intervention period: >6 months. CAT, COPD Assessment Test.
Figure 10Meta-analysis of Tai on SGRQ in short time intervention period. (A) Tai Chi group versus control group; (B) Tai Chi group versus exercise group. Short time intervention period: ≤3 months; medium time intervention period: 4–6 months; long time intervention period: >6 months. SGRQ, St. George’s Respiratory Questionnaire.
Figure 11Meta-analysis of Tai on CRQ in short time intervention period. Tai Chi group versus control group. Short time intervention period: ≤3 months; medium time intervention period: 4–6 months; long time intervention period: >6 months. CRQ, Chronic Respiratory Disease Questionnaire.
Figure 12Meta-analysis of Tai on HAD (anxiety) in short time intervention period. Tai Chi group versus control group. Short time intervention period: ≤3 months; medium time intervention period: 4–6 months; long time intervention period: >6 months. HAD, hospital anxiety and depression Scale.
Figure 13Meta-analysis of Tai on HAD (depression) in short time intervention period. Tai Chi group versus control group. Short time intervention period: ≤3 months; medium time intervention period: 4–6 months; long time intervention period: >6 months. HAD, hospital anxiety and depression Scale.
Summary of results
| Outcomes | No. of trials | No. of participants | Mean difference (95% CI) | Heterogeneity (I2) |
|---|---|---|---|---|
| FVC | ||||
| TC | ||||
| Short term | 2 | 183 | 0.12 (0.03, 0.21); P=0.01 | 0% |
| TC | ||||
| Short term | 4 | 511 | 0.38 (−0.33, 1.09); P=0.29 | 98% |
| FEV1 | ||||
| TC | ||||
| Short term | 3 | 219 | 0.13 (0.06, 0.2); P=0.0002 | 12% |
| Mid term | 3 | 136 | 0.17 (0.04, 0.30); P=0.01 | 59% |
| TC | ||||
| Short term | 5 | 547 | 0.06 (−0.01, 0.14); P=0.08 | 41% |
| Mid term | 2 | 228 | 0.03 (−0.09, 0.14); P=0.62 | 0% |
| FEV1% | ||||
| TC | ||||
| Short term | 3 | 142 | 0.22 (−1.80, 2.23); P=0.83 | 0% |
| Mid term | 2 | 96 | 3.33 (−1.17, 7.84); P=0.15 | 30% |
| Long term | 2 | 96 | 5.78 (−3.75, 15.31); P=0.23 | 73% |
| FEV1/FVC | ||||
| TC | ||||
| Short term | 3 | 120 | 3.33 (−2.92, 9.58); P=0.3 | 61% |
| TC | ||||
| Short term | 3 | 170 | 7.05 (3.51, 10.6); P<0.0001 | 73% |
| MWD | ||||
| TC | ||||
| Short term | 6 | 363 | 24.29 (6.29, 42.28); P=0.008 | 77% |
| Mid term | 2 | 76 | 37.35 (3.96, 70.75); P=0.03 | 70% |
| Long term | 2 | 96 | 47.73 (−14.96, 110.42); P=0.14 | 77% |
| TC | ||||
| Short term | 6 | 621 | 7.53 (2.18, 12.89); P=0.006 | 0% |
| Mid term | 2 | 228 | 10.63 (−7.82, 29.09); P=0.26 | 0% |
| CAT | ||||
| TC | ||||
| Short term | 4 | 216 | −3.71 (−6.33, −1.08); P=0.006 | 63% |
| Long term | 2 | 312 | −7.08 (-13.33, −0.84); P=0.03 | 91% |
| TC | ||||
| Short term | 3 | 170 | −3.62 (−7.87, 0.62); P=0.09 | 91% |
| SGRQ | ||||
| TC | ||||
| Short term | 3 | 257 | −8.66 (−14.60, −2.72); P=0.004 | 64% |
| TC | ||||
| Short term | 4 | 525 | −1.93 (−4.57, 0.72); P=0.15 | 38% |
| CRQ | ||||
| TC | ||||
| Short term | 2 | 52 | 2.16 (1.49, 2.83); P<0.00001 | 46% |
| HAD (anxiety) | ||||
| TC | ||||
| Short term | 2 | 88 | −1.04 (−1.58, −0.51); P=0.0001 | 0% |
| HAD (depression) | ||||
| TC | ||||
| Short term | 2 | 88 | −1.25 (−1.77, −0.73); P<0.00001 | 0% |
TC, Tai Chi; FVC, forced volume capacity; FEV1%, FEV1 percent predicted normal values; FEV1, forced expiratory volume in 1 s; FEV1/FVC, the ratio of FEV1 to FVC; 6MWD, six-minute walking distance; CAT, COPD Assessment Test; SGRQ, St. George’s Respiratory Questionnaire; CRQ, Chronic Respiratory Disease Questionnaire; HAD, hospital anxiety and depression scale.